0.00Open0.00Pre Close0 Volume0 Open Interest10.00Strike Price0.00Turnover291.87%IV-106.61%PremiumDec 20, 2024Expiry Date5.16Intrinsic Value100Multiplier25DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.7159Delta0.0927Gamma0.86Leverage Ratio-0.0243Theta-0.0048Rho-0.62Eff Leverage0.0043Vega
Candel Therapeutics Stock Discussion
5.30+
Now Let's Get That 10.+ Back!
Let's Get 5.+
Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma
Candel Therapeutics announced preclinical results for CAN-3110 in melanoma models, showing potential expansion beyond high-grade glioma treatment. CAN-3110, a first-in-class HSV-1 oncolytic viral immunotherapy, demonstrated potent antitumor activity in both in vitro human cel...
No comment yet